These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 24096267)
1. Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Yoshioka Y; Konishi I Cancer Biol Ther; 2014 Jan; 15(1):22-5. PubMed ID: 24096267 [TBL] [Abstract][Full Text] [Related]
2. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Matsumura N; Mandai M; Okamoto T; Yamaguchi K; Yamamura S; Oura T; Baba T; Hamanishi J; Kang HS; Matsui S; Mori S; Murphy SK; Konishi I Cancer Sci; 2010 Dec; 101(12):2658-63. PubMed ID: 21040214 [TBL] [Abstract][Full Text] [Related]
3. Multi-kinase inhibition in ovarian cancer. Dent P Cancer Biol Ther; 2014 Jan; 15(1):1-2. PubMed ID: 24309512 [TBL] [Abstract][Full Text] [Related]
4. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401 [TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Strumberg D Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853 [TBL] [Abstract][Full Text] [Related]
7. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. Smolle E; Taucher V; Petru E; Haybaeck J Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319 [TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268 [No Abstract] [Full Text] [Related]
10. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883 [TBL] [Abstract][Full Text] [Related]
12. [Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report]. Yoshinaga A; Ichiyanagi N; Kamata S Nihon Hinyokika Gakkai Zasshi; 2013 Jul; 104(4):609-11. PubMed ID: 23971370 [TBL] [Abstract][Full Text] [Related]
13. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Berk V; Kaplan MA; Tonyali O; Buyukberber S; Balakan O; Ozkan M; Demirci U; Ozturk T; Bilici A; Tastekin D; Ozdemir N; Unal OU; Oflazoglu U; Turkmen E; Erdogan B; Uyeturk U; Oksuzoglu B; Cinkir HY; Yasar N; Gumus M Asian Pac J Cancer Prev; 2013; 14(12):7367-9. PubMed ID: 24460304 [TBL] [Abstract][Full Text] [Related]
14. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. Devapatla B; Sharma A; Woo S PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070 [TBL] [Abstract][Full Text] [Related]
15. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report. Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876 [TBL] [Abstract][Full Text] [Related]